BRPI0518242A2 - mÉtodos terapÊuticos e de liberaÇço de agonistas de prostaglandina ep4 - Google Patents

mÉtodos terapÊuticos e de liberaÇço de agonistas de prostaglandina ep4

Info

Publication number
BRPI0518242A2
BRPI0518242A2 BRPI0518242-5A BRPI0518242A BRPI0518242A2 BR PI0518242 A2 BRPI0518242 A2 BR PI0518242A2 BR PI0518242 A BRPI0518242 A BR PI0518242A BR PI0518242 A2 BRPI0518242 A2 BR PI0518242A2
Authority
BR
Brazil
Prior art keywords
prostaglandin
agonists
therapeutic
prodrug
release methods
Prior art date
Application number
BRPI0518242-5A
Other languages
English (en)
Inventor
Yariv Donde
Mark Holoboski
Todd S Gac
Wha Bim Im
David W Old
Karen M Kedzie
Daniel W Gil
John E Donello
Robert M Burk
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BRPI0518242A2 publication Critical patent/BRPI0518242A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

MÉTODOS TERAPÊUTICOS E DE LIBERAÇçO DE AGONISTAS DE PROSTAGLANDINA EP~ 4~. A presente invenção refere-se a um composto compreendendo um pró-fármaco de uma agonista de prostaglandina EP~ 4~, em que o referido pró-fármaco é um éster, éter, ou amida de um carboidrato; ou o referido pró- fármaco é um éster, éter, ou amida de um aminoácido é aqui descrito. Manu- tenção da barreira mucosal colôníca pelo método compreendendo adminis- trar uma quantidade terapeuticamente eficaz de uma agonista de prosta- glandína EP~ 4~ a um cólon de um mamífero é também aqui descrita. As formas de dosagem, medicamentos, e composições, relacionadas ao método são também descritas.
BRPI0518242-5A 2004-10-26 2005-10-24 mÉtodos terapÊuticos e de liberaÇço de agonistas de prostaglandina ep4 BRPI0518242A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62242204P 2004-10-26 2004-10-26
PCT/US2005/038303 WO2006047476A2 (en) 2004-10-26 2005-10-24 Therapeutic and delivery methods of prostaglandin ep4 agonists

Publications (1)

Publication Number Publication Date
BRPI0518242A2 true BRPI0518242A2 (pt) 2008-11-11

Family

ID=35840538

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518242-5A BRPI0518242A2 (pt) 2004-10-26 2005-10-24 mÉtodos terapÊuticos e de liberaÇço de agonistas de prostaglandina ep4

Country Status (7)

Country Link
US (1) US20080132543A1 (pt)
EP (1) EP1805139A2 (pt)
JP (1) JP2008518013A (pt)
AU (1) AU2005299473B2 (pt)
BR (1) BRPI0518242A2 (pt)
CA (1) CA2585367A1 (pt)
WO (1) WO2006047476A2 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1841733A2 (en) * 2004-11-08 2007-10-10 Allergan, Inc. Substituted pyrrolidone compounds as prostaglandin ep4 agonists
US20060281818A1 (en) * 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
US20070232660A1 (en) * 2006-04-04 2007-10-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
WO2008076703A1 (en) * 2006-12-18 2008-06-26 Allergan, Inc. Methods and compositions for treating gastrointestinal disorders
JP5836262B2 (ja) 2009-03-19 2015-12-24 フェイト セラピューティクス， インコーポレイテッド サイクリックａｍｐエンハンサーおよび／またはｅｐリガンドを含む組成物、ならびにこれを調製および使用する方法
WO2011047048A1 (en) 2009-10-14 2011-04-21 Gemmus Pharma, Inc. Combination therapy treatment for viral infections
CN112501118A (zh) 2010-08-12 2021-03-16 菲特治疗公司 改进的造血干细胞和祖细胞疗法
EP2694120A1 (en) * 2011-04-07 2014-02-12 Allergan, Inc. Devices, compositions and methods utilizing ep4 and ep2 receptor agonists for preventing, reducing or treating capsular contracture
JP6285863B2 (ja) 2011-09-30 2018-02-28 ブルーバード バイオ， インコーポレイテッド 改善されたウイルスによる形質導入のための化合物
CN112375734A (zh) 2011-12-02 2021-02-19 菲特治疗公司 增强的干细胞组合物
US10111907B2 (en) 2011-12-02 2018-10-30 Fate Therapeutics, Inc. Methods of treating ischemia
EP2968416A4 (en) 2013-03-15 2016-08-17 Fate Therapeutics Inc BIOLOGICAL ACTIVITY TESTING OF CELLS FOR A THERAPEUTIC POTENTIAL
US9943545B2 (en) 2013-03-15 2018-04-17 Fate Therapeutics, Inc. Stem cell culture media and methods of enhancing cell survival
EP3030252B1 (en) 2013-08-09 2018-11-07 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
US11326183B2 (en) 2016-02-12 2022-05-10 Bluebird Bio, Inc. VCN enhancer compositions and methods of using the same
RU2744603C2 (ru) 2016-02-12 2021-03-11 Блубёрд Био, Инк. Композиции, повышающие число копий вектора (чкв), и способы их применения
CN114340631A (zh) 2019-05-21 2022-04-12 阿德利克斯股份有限公司 用于降低患者的血清磷酸盐的组合

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5714346B2 (pt) * 1973-07-12 1982-03-24
KR880012221A (ko) * 1987-04-13 1988-11-26 사노 가즈오 에스테르 또는 아미드를 활성성분으로 함유하는 약제 조성물
US6043275A (en) * 1998-04-16 2000-03-28 Ono Pharmaceutical Co., Ltd. 3,7-dithiaprostanoic acid derivative
TWI249520B (en) * 1998-07-15 2006-02-21 Ono Pharmaceutical Co 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient
WO2000015608A1 (en) * 1998-09-14 2000-03-23 Ono Pharmaceutical Co., Ltd. φ-SUBSTITUTED PHENYL-PROSTAGLANDIN E DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT
US20020002140A1 (en) * 2000-01-14 2002-01-03 Holick Michael F. Novel bisphosphonates and uses thereof
SK5562003A3 (en) * 2000-11-27 2004-08-03 Pfizer Prod Inc EP4 receptor selective agonists in the treatment of osteoporosis
US20050222094A1 (en) * 2001-06-14 2005-10-06 Burk Robert M Treatment of inflammatory bowel disease
US20030027853A1 (en) * 2001-06-14 2003-02-06 Allergan Sales, Inc. 3, 7or3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
BR0211201A (pt) * 2001-07-16 2004-07-13 Hoffmann La Roche Composto, processo para a preparação desse composto, sua utilização, composição farmacêutica que compreende o mesmo e método para o tratamento de uma enfermidade em um mamìfero
CN101921220B (zh) * 2001-07-23 2013-05-22 小野药品工业株式会社 治疗与骨质损失有关的疾病的含有ep4激动剂作为活性成分的药物组合物
CA2478653A1 (en) * 2002-03-18 2003-09-25 Pfizer Products Inc. Methods of treatment with selective ep4 receptor agonists
US7053085B2 (en) * 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
KR100752891B1 (ko) * 2003-01-10 2007-08-28 에프. 호프만-라 로슈 아게 프로스타글란딘 작용제로서 2-피페리돈 유도체
PL209130B1 (pl) * 2003-02-11 2011-07-29 Allergan Inc Pochodne kwasu 10,10-dialkiloprostanowego, roztwór do stosowania w okulistyce, sposób wytwarzania związków pośrednich i zastosowanie pochodnych kwasu 10,10-dialkiloprostanowego
US6875787B2 (en) * 2003-02-11 2005-04-05 Allergan, Inc. 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure

Also Published As

Publication number Publication date
CA2585367A1 (en) 2006-05-04
JP2008518013A (ja) 2008-05-29
EP1805139A2 (en) 2007-07-11
AU2005299473A1 (en) 2006-05-04
AU2005299473B2 (en) 2012-06-28
WO2006047476A3 (en) 2006-09-28
US20080132543A1 (en) 2008-06-05
WO2006047476A2 (en) 2006-05-04

Similar Documents

Publication Publication Date Title
BRPI0518242A2 (pt) mÉtodos terapÊuticos e de liberaÇço de agonistas de prostaglandina ep4
AR048973A1 (es) (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)amida del acido 4-hidroxi-4-metil-piperidin-1-carboxilico. proceso de preparacion y composiciones farmaceuticas
NO20091620L (no) Boronsyre og estere som inhibitorer av fettsyreamidhydrolaser
MY139577A (en) Anti-inflammatory androstane derivative
JP2008510795A (ja) 新規バイオ開裂性リンカー
MX2011012627A (es) Derivados aminobutiricos sustituidos como inhibidores de nepralisina.
ECSP109905A (es) Moduladores de receptor 7 tipo toll
BRPI0414907A (pt) formulações farmacêuticas com liberação sustentada injetáveis, orais ou tópicas
SG10201806714PA (en) C7-fluoro substituted tetracycline compounds
BR112012018384A2 (pt) composição farmacêutica sólida com intensificadores e métodos de preparação da mesma.
CO6321221A2 (es) Formulaciones farmaceuticas de fenilefrina y composiciones para absorcion transmucosal
WO2003099338A3 (en) Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
WO2006043655A1 (ja) 吸入用医薬組成物
MX2011007737A (es) Derivados de hidroximetil isoxazol como moduladores de acido gamma-aminobutirico a.
BRPI0506493A (pt) combinações terapêuticas
JP2948658B2 (ja) 新規アミノ酸誘導体、その製造方法およびその医薬組成物
AU2007341218B2 (en) Isosorbide mononitrate derivatives for the treatment of intestinal disorders
MX2023003846A (es) Compuesto de bifenilo como inmunomodulador, metodo de preparacion del mismo y aplicacion del mismo.
MX2022006151A (es) Derivados de 1,2,4-oxadiazol como agonistas del receptor hepatico x.
UA122762C2 (uk) Пероральна композиція 9-[(2,2-диметилпропіламіно)-метил]-міноцикліну або його солі, тверда пресована дозована форма, композиція для ін'єкцій, застосування та спосіб приготування фармацевтичної композиції
BR0311642A (pt) Formulação de divalproex de sódio de liberação aumentada
AR050043A1 (es) Metodos para mejorar la biodisponibilidad y composicion farmaceutica para trastornos cardiovasculares
JP6402110B2 (ja) アミノペプチダーゼｎおよびネプリライシンの混合阻害剤
US20230257357A1 (en) Probenecid compounds for the treatment of inflammasome-mediated lung disease
WO2020263995A1 (en) Hydroxamic acids comprising pyrazole moiety and uses thereof

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B15K Others concerning applications: alteration of classification

Ipc: C07C 405/00 (2006.01), A61K 47/54 (2017.01), A61K

B11T Dismissal of application maintained [chapter 11.20 patent gazette]